Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors

Gastrointestinal stromal tumors (GISTs) are common ICC precursor sarcomas, which are considered to be a potential malignant mesenchymal tumor driven by specific KIT or PDGFRA signals in the gastrointestinal tract. The standard treatment for GIST without metastasis is surgical resection. GIST with me...

Full description

Bibliographic Details
Main Authors:	Lei Cao, Kunming Zheng, Yanhong Liu, Peng Song, Chuntao Wang, Hongzhi Wang, Nan Wang, Shiwu Zhang, Yongjie Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Genetics
Subjects:	GIST gastrointestinal stromal tumor imatinib DEG (differentially expressed gene) analysis resistance gene chip
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.878145/full

Similar Items

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
by: Shang-Yu Wang, et al.
Published: (2019-03-01)

Sarcomas del estroma gastrointestinal tratados con Imatinib®: presentación de 2 casos Gastrointestinal stromal tumors treated with Imatinib®: report of 2 cases
by: Mayté Lima, et al.
Published: (2006-06-01)

Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib
by: Qu H, et al.
Published: (2022-03-01)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
by: Juan Liu, et al.
Published: (2022-04-01)

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
by: Maria A. Pantaleo, et al.
Published: (2022-05-01)

Appropriate durations of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumor (GIST) the better choice, for the year 2010
by: Lucia Tozzi
Published: (2015-10-01)

Diagnosis and management of high risk gastrointestinal stromal tumor in first trimester pregnancy: A case report and review of the literature
by: Christina M. Sheedy, et al.
Published: (2023-05-01)

Type and Gene Location of <i>KIT</i> Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
by: Lorena Incorvaia, et al.
Published: (2021-02-01)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
by: Nikolaos Vassos, et al.
Published: (2021-02-01)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
by: Adnan Asif Parvez Ghias, et al.
Published: (2018-03-01)

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)
by: Fousséni Alassani, et al.
Published: (2019-11-01)

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
by: Thanaporn Bussabawalai, et al.
Published: (2019-01-01)

Surgical Approaches and Oncological Outcomes in the Management of Duodenal Gastrointestinal Stromal Tumors (GIST)
by: Nikolaos Vassos, et al.
Published: (2021-09-01)

Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
by: Eline L. Giraud, et al.
Published: (2023-05-01)

<i>KIT</i> and <i>PDGFRA</i> Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
by: Heikki Joensuu
Published: (2023-07-01)

Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
by: Claudia Angela Maria Fulgenzi, et al.
Published: (2022-06-01)

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
by: Seidel Christoph, et al.
Published: (2012-05-01)

Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
by: Xiangchen Hu, et al.
Published: (2022-09-01)

Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice
by: Szymon Macioszek, et al.
Published: (2023-04-01)

Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour
by: Alexandre Bertucci, et al.
Published: (2019-08-01)

Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report
by: Elisa Tassinari, et al.
Published: (2023-12-01)

MORPHOLOGICAL AND IMMUNOCYTOCHEMICAL CHARACTERISTICS OF STROMAL GASTROINTESTINAL TUMORS
by: Ivan Ilić, et al.
Published: (2010-09-01)

Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib
by: Tianxiang Lei, et al.
Published: (2021-01-01)

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis
by: Jiang X, et al.
Published: (2023-03-01)

A ruptured gastrointestinal stromal tumour of the small intestine: a case report
by: Ivan Lolli, et al.
Published: (2015-10-01)

Gastrointestinal Stromal Tumors: 10-Year Experience in Cancer Center—The Ottawa Hospital (TOH)
by: Abdulhameed Alfagih, et al.
Published: (2022-09-01)

Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
by: Hui-Hua Hsiao, et al.
Published: (2006-12-01)

Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor
by: Marya Kozinova, et al.
Published: (2021-07-01)

Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors – a real-world multi-center study
by: Shaoqing Huang, et al.
Published: (2023-04-01)

Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
by: Azadeh Amirnasr, et al.
Published: (2019-06-01)

Gastrointestinal Stromal Tumor (GIST) from esophagus to anorectum – diagnosis, response evaluation and surveillance on computed tomography (CT) scan
by: Sushil N Panbude, et al.
Published: (2019-04-01)

Surgical intervention of a giant gastric gastrointestinal stromal tumor following neoadjuvant therapy with imatinib
by: Chien-Yang Wang, et al.
Published: (2018-01-01)

Imatinib Regulates <i>miR-483-3p</i> and Mitochondrial Respiratory Complexes in Gastrointestinal Stromal Tumors
by: Wen-Kuan Huang, et al.
Published: (2021-09-01)

Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
by: Xiaobin Cheng, et al.
Published: (2021-07-01)

Liver metastases 2 years after resection of a very-low-risk duodenal gastrointestinal stromal tumor: a case report
by: Junya Mita, et al.
Published: (2022-10-01)

Polekowe zapalenie skóry wywołane imatynibem u pacjentki z nowotworem podścieliska przewodu pokarmowego – opis przypadku
by: Hanna Myśliwiec, et al.
Published: (2011-07-01)

Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors
by: Qiaowei Lin, et al.
Published: (2020-01-01)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
by: Thirasastr P, et al.
Published: (2023-02-01)

Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
by: Ryota Niikura, et al.
Published: (2016-05-01)

Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments
by: Chi Yan, et al.
Published: (2022-06-01)